These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

675 related items for PubMed ID: 12885750

  • 1. Norepinephrine precursor therapy in neurogenic orthostatic hypotension.
    Kaufmann H, Saadia D, Voustianiouk A, Goldstein DS, Holmes C, Yahr MD, Nardin R, Freeman R.
    Circulation; 2003 Aug 12; 108(6):724-8. PubMed ID: 12885750
    [Abstract] [Full Text] [Related]

  • 2. L-Dihydroxyphenylserine (L-DOPS): a norepinephrine prodrug.
    Goldstein DS.
    Cardiovasc Drug Rev; 2006 Aug 12; 24(3-4):189-203. PubMed ID: 17214596
    [Abstract] [Full Text] [Related]

  • 3. L-threo-dihydroxyphenylserine (L-threo-DOPS; droxidopa) in the management of neurogenic orthostatic hypotension: a multi-national, multi-center, dose-ranging study in multiple system atrophy and pure autonomic failure.
    Mathias CJ, Senard JM, Braune S, Watson L, Aragishi A, Keeling JE, Taylor MD.
    Clin Auton Res; 2001 Aug 12; 11(4):235-42. PubMed ID: 11710796
    [Abstract] [Full Text] [Related]

  • 4. Substantial renal conversion of L-threo-3,4-dihydroxyphenylserine (droxidopa) to norepinephrine in patients with neurogenic orthostatic hypotension.
    Lamotte G, Holmes C, Sullivan P, Goldstein DS.
    Clin Auton Res; 2019 Feb 12; 29(1):113-117. PubMed ID: 30229336
    [Abstract] [Full Text] [Related]

  • 5. Clinical pharmacokinetics of the norepinephrine precursor L-threo-DOPS in primary chronic autonomic failure.
    Goldstein DS, Holmes C, Kaufmann H, Freeman R.
    Clin Auton Res; 2004 Dec 12; 14(6):363-8. PubMed ID: 15666063
    [Abstract] [Full Text] [Related]

  • 6. L-dihydroxyphenylserine (Droxidopa): a new therapy for neurogenic orthostatic hypotension: the US experience.
    Kaufmann H.
    Clin Auton Res; 2008 Mar 12; 18 Suppl 1():19-24. PubMed ID: 18368303
    [Abstract] [Full Text] [Related]

  • 7. The treatment of neurogenic orthostatic hypotension with 3,4-DL-threo-dihydroxyphenylserine: a randomized, placebo-controlled, crossover trial.
    Freeman R, Landsberg L, Young J.
    Neurology; 1999 Dec 10; 53(9):2151-7. PubMed ID: 10599797
    [Abstract] [Full Text] [Related]

  • 8. The discovery of the pressor effect of DOPS and its blunting by decarboxylase inhibitors.
    Kaufmann H.
    J Neural Transm Suppl; 2006 Dec 10; (70):477-84. PubMed ID: 17017570
    [Abstract] [Full Text] [Related]

  • 9. Effects of carbidopa and entacapone on the metabolic fate of the norepinephrine prodrug L-DOPS.
    Goldstein DS, Holmes C, Sewell L, Pechnik S, Kopin IJ.
    J Clin Pharmacol; 2011 Jan 10; 51(1):66-74. PubMed ID: 20220040
    [Abstract] [Full Text] [Related]

  • 10. Supine plasma NE predicts the pressor response to droxidopa in neurogenic orthostatic hypotension.
    Palma JA, Norcliffe-Kaufmann L, Martinez J, Kaufmann H.
    Neurology; 2018 Oct 16; 91(16):e1539-e1544. PubMed ID: 30232253
    [Abstract] [Full Text] [Related]

  • 11. Effects of L-threo-3,4-dihydroxyphenylserine on orthostatic hypotension in hemodialysis patients.
    Iida N, Koshikawa S, Akizawa T, Tsubakihara Y, Marumo F, Akiba T, Kawaguchi Y, Imada A, Yamazaki C, Suzuki M.
    Am J Nephrol; 2002 Oct 16; 22(4):338-46. PubMed ID: 12169865
    [Abstract] [Full Text] [Related]

  • 12. Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial.
    Kaufmann H, Freeman R, Biaggioni I, Low P, Pedder S, Hewitt LA, Mauney J, Feirtag M, Mathias CJ, NOH301 Investigators.
    Neurology; 2014 Jul 22; 83(4):328-35. PubMed ID: 24944260
    [Abstract] [Full Text] [Related]

  • 13. Droxidopa in patients with neurogenic orthostatic hypotension associated with Parkinson's disease (NOH306A).
    Hauser RA, Hewitt LA, Isaacson S.
    J Parkinsons Dis; 2014 Jul 22; 4(1):57-65. PubMed ID: 24326693
    [Abstract] [Full Text] [Related]

  • 14. Droxidopa in neurogenic orthostatic hypotension.
    Kaufmann H, Norcliffe-Kaufmann L, Palma JA.
    Expert Rev Cardiovasc Ther; 2015 Jul 22; 13(8):875-91. PubMed ID: 26092297
    [Abstract] [Full Text] [Related]

  • 15. Beneficial attenuating effect of L-threo-3,4-dihydroxyphenylserine on postural hypotension in anesthetized rats.
    Satoh S, Oyabe A, Tanno M, Suzuki-Kusaba M.
    Arzneimittelforschung; 1989 Sep 22; 39(9):1123-9. PubMed ID: 2511849
    [Abstract] [Full Text] [Related]

  • 16. Neurogenic orthostatic hypotension in Parkinson's disease: evaluation, management, and emerging role of droxidopa.
    Isaacson SH, Skettini J.
    Vasc Health Risk Manag; 2014 Sep 22; 10():169-76. PubMed ID: 24729712
    [Abstract] [Full Text] [Related]

  • 17. [Effects of L-threo-Dops on orthostatic hypotension in Parkinson's disease].
    Yanagisawa N, Ikeda S, Hashimoto T, Hanyu N, Nakagawa S, Fujimori N, Ushiyama M.
    No To Shinkei; 1998 Feb 22; 50(2):157-63. PubMed ID: 9513205
    [Abstract] [Full Text] [Related]

  • 18. Randomized withdrawal study of patients with symptomatic neurogenic orthostatic hypotension responsive to droxidopa.
    Biaggioni I, Freeman R, Mathias CJ, Low P, Hewitt LA, Kaufmann H, Droxidopa 302 Investigators.
    Hypertension; 2015 Jan 22; 65(1):101-7. PubMed ID: 25350981
    [Abstract] [Full Text] [Related]

  • 19. Droxidopa for the short-term treatment of symptomatic neurogenic orthostatic hypotension in Parkinson's disease (nOH306B).
    Hauser RA, Isaacson S, Lisk JP, Hewitt LA, Rowse G.
    Mov Disord; 2015 Apr 15; 30(5):646-54. PubMed ID: 25487613
    [Abstract] [Full Text] [Related]

  • 20. DL-Threo-3,4-dihydroxyphenylserine does not exert a pressor effect in orthostatic hypotension.
    Hoeldtke RD, Cilmi KM, Mattis-Graves K.
    Clin Pharmacol Ther; 1984 Sep 15; 36(3):302-6. PubMed ID: 6432398
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.